Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Maciej M. Mrugała, Nicholas Butowski et al.|The Lancet Oncology|2017Cited by 1.1k